Microglia engineering and replacement to treat brain disease

Introduction

Microglia are highly versatile brain resident cells that offer tremendous therapeutic opportunities. They are instrumental for maintaining healthy brain physiology and act as the primary modulators of neuroinflammation and disease. Microglial dysfunction has been convincingly linked to a myriad of neurological disorders, making these cells a prime target for therapeutic intervention.

Unique Characteristics of Microglia

Remarkably, microglia are embryo-derived cells that self-maintain for life, with negligible replacement by the bone marrow. This astonishing self-renewal capacity offers a unique opportunity for cell therapy. The ability to replace dysfunctional microglia with healthy or genetically enhanced counterparts may transform the way we treat brain disease.

Challenges in Microglial Replacement

But how can we replace a cell that is so adept at self-renewal in a tissue that is shielded from the periphery? Currently, there are no translatable approaches for the specific replacement of microglia. Furthermore, bone marrow progenitors are unable to adopt the embryonic microglial phenotype.

Research Objectives

By building on our unpublished observations and developing innovative technologies, I aim to lay the foundation for microglial replacement therapy. We intend to develop an original and translatable strategy for the specific and near-complete replacement of embryonic microglia with adoptively transferred progenitors.

Methodology

Next, by combining iPSC differentiation with genetic barcoding, single-cell analysis, and in vivo screening, we aim to identify progenitors that efficiently traffic to the brain and engraft as bona fide microglia.

Future Directions

Moreover, we will investigate how we can transform microglia into local protein production factories, as a potential basis to treat neurodegenerative diseases. Finally, we will set up in vivo pooled CRISPR screens to identify the gene networks that can modulate and positively enhance microglial disease responses.

Conclusion

ReplaceMi has the potential to result in a new and eagerly awaited breakthrough in treating brain disease.